Introduction
Nasopharyngeal carcinoma (NPC) has a high incidence rate in Southern China (1) .
Although the majority of primary NPC cases can be successfully treated with radiotherapy, local recurrence and metastatic NPC are still major problems in the treatment of NPC (2) . In a preclinical cell model, Lun et al recently demonstrated that a subpopulation of Epstein -Barr virus (EBV) and cluster of differentiation (CD)44-positive NPC cells is resistant to chemotherapy and exhibits properties of cancer stem cells (CSCs) (3) . The transmembrane glycoprotein CD44 is generally considered a multifunctional protein that participates in signaling pathways involved in cancer dissemination. The versatility of CD44 in the regulation of cell growth and migration is due to its interaction with various cellular molecules such as ankyrin, ezrin, radixin and moesin (ERM proteins) (4) .
The developmental signaling pathways Wnt, Notch and Hedgehog are known to be used by CSCs to regulate cell growth and differentiation. In addition to these stem cell-associated signaling pathways, recent studies also indicate that both microRNA (miRNA or miR) (5, 6) and epigenetic mechanisms (7) (8) (9) serve an important role in the regulation of CSC growth and differentiation. In NPC, it has been recently identified that the CBP/catenin antagonist and Wnt modulator ICG-001 could inhibit the growth of EBV-positive NPC cells via downregulated expression of the tumor suppressor/pro-differentiator miR-145. It was also observed that ICG-001 reduced the P r o o f population of cells expressing Sox2 Hi /CD44 Hi (10) . In the present study, the role of miR-150 in the expression of CD44 in ICG-001-treated NPC cells was further demonstrated.
Materials and methods
Cell culture. The EBV-positive C666-1 NPC cell line was maintained in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin (P/S; Gibco; Thermo Fisher Scientific, Inc.). The NPC xenograft-derived EBV-positive C17 NPC cell line (11) supplemented with 5% FBS and 5% newborn calf serum with 1% P/S. The C666-1 and HONE-1 cell lines (12) (13) (14) (15) were obtained from the Hong Kong NPC AoE Research Tissue Bank and Cell Line Repository, and were authenticated using the AmpFLSTR Identifier PCR Amplification Kit (Thermo Fisher Scientific, Inc.) (16, 17) .
To further ensure the HONE-1 cells used in the present study were free from HeLa cell contamination, a single duplex detection polymerase chain reaction (PCR) assay targeting a HeLa-specific L1 retrotransposon insertion as described by Rahbari et al (18) was conducted. NPC cells were treated with ICG-001 or dimethyl sulfoxide (vehicle control) in the corresponding culture medium. All cell lines were cultured at 37˚C in a 5% CO 2 humidified incubator. ICG-001 at 10 µM was used for cell treatment unless otherwise specified. Samples were then analyzed by immunoblotting as described above. 
P r o o f

Tumor sphere formation assay. A tumor sphere formation assay was performed as previously described (8) . Briefly, C666-1 cells (2,000 cells/well) in DMEM/F12 (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 20 ng/ml epidermal growth factor (EGF) (Sigma-Aldrich; Merck KGaA), 20 ng/ml fibroblast growth factor (FGF) (Cell Signaling Technology, Inc.) and 20 ng/ml insulin-like growth factor (IGF) (Cell Signaling Technology, Inc.) were seeded onto 24-well ultra-low attachment culture plates (Corning Incorporated). The cultures were fed with growth factors every 2-3 days. Upon incubation, the tumor spheres were observed under a microscope, and the size of those tumor spheres measuring >20 µm was determined by ImageJ software.
Target gene prediction for miRNA. Potential targets of miR-150 was predicted using an online bioinformatics software TargetScan Human, version 6.2 (http://www.targetscan.org/vert_61/). Immunohistochemical (IHC) staining. Mouse xenograft tumors were generated by injecting C666-1 cells into BALB/c nu/nu mice according to our previous study (10) . 
Results
ICG-001 inhibits canonical
ICG-001 inhibits the migration of NPC cells.
Our group previously demonstrated that ICG-001 could restore the expression of the tumor suppressor miR-145 and inhibit the growth of CSC-enriched NPC spheroid cells (10) . The present study further revealed that ICG-001 could inhibit the migration of NPC cells in a Transwell migration assay ( Fig. 1B) . Since ICG-001 is capable of interfering with the β-catenin/CBP P r o o f downstream signaling, it was hypothesized that siRNA silencing of β-catenin or CBP expression could also inhibit the migration of NPC cells. The present results clearly demonstrated that siRNA knockdown of the protein expression of β-catenin (Fig. 1C) or CBP (Fig. 1D ) resulted in reduced migration of NPC cells (Fig. 1E and 1F) . These observations suggest that β-catenin and CBP are involved in the regulation of migration of NPC cells.
Involvement of CD44 in the migration of NPC cells. The expression of CD44 has
previously been shown to be controlled by Wnt/β-catenin signaling (22). In the present study, the expression of CD44 was determined in ICG-001-treated NPC cells.
The results presented in Fig. 2A and B To confirm the involvement of CD44 in the migration of NPC cells, the expression of CD44 was knocked down by transfection of the NPC cells with CD44 siRNA. The results shown in Fig. 3A revealed that CD44 siRNA could reduce the protein expression of CD44, and this effect was accompanied by a significant reduction in the migration of NPC cells (Fig. 3B ). Ezrin is a key molecule linking the plasma membrane components with the cytoskeleton, and its association with CD44 is particularly important in mediating cell migration (23,24). To further confirm the interaction of CD44 with ezrin in NPC cells, co-IP was performed using total cell P r o o f lysates. The results of Fig. 3C revealed Co-IP between CD44 and ezrin, indicating that CD44 interacts with the above migration-regulatory component in NPC cells. Notably, the capability of CD44 siRNA-transfected cells to form tumor spheres was similar to that of control siRNA-transfected cells (Fig. 3D) , indicating that CD44 is not involved in the growth of C666-1 tumor spheres. Taken together, the results from these studies indicate that CD44 is involved in the regulation of the migration of NPC cells.
ICG-001 restores the expression of miR-150. A recent study on miRNA expression
demonstrated that the expression level of miR-150 is reduced in NPC tissues (25) . To evaluate the possible involvement of miR-150 in the ICG-001-mediated inhibition of CD44 expression, the expression of miR-150 was determined in C666-1 cells under monolayer and spheroid culture conditions. The results in Fig. 4A -C revealed that ICG-001 could restore miR-150 expression under these culture conditions. Restored expression of miR-150 was also observed in EBV-positive C17 (Fig. 4D ) and EBV-negative HONE-1 (Fig. 4E ) NPC cells.
It has been previously reported that the HONE-1 cell line appears to bear part of the HeLa genomic sequence, suggesting that it may be a derivative of HeLa cervical carcinoma cells and another cell of unknown origin (26) . To ensure that the HONE-1 cells used in the present study were not contaminated by HeLa cells, a single duplex detection PCR assay was performed. The results revealed that no L1 insertion was detected in HONE-1 cells, indicating that the HONE-1 cells used in the present study are not likely to be cross-contaminated with HeLa cells (data not shown).
CD44 is a direct target of miR-150. In addition to the reduced expression of CD44 mRNA, the present study sought to examine whether additional mechanisms are also involved in the downregulated expression of CD44 in ICG-001-treated NPC P r o o f cells. When C666-1 cells were transfected with the precursor form of miR-150 (pre-miR-150; Fig. 5A ), and the impact of overexpression of miR-150 on the protein expression of CD44 was first evaluated. A clear reduction in CD44 protein expression was noticed in pre-miR-150-transfected cells (Fig. 5B) , indicating that miR-150 may be involved in the ICG-001-induced downregulated expression of CD44 in NPC cells.
To further confirm the specific action of miR-150, a 3'-UTR reporter assay was used to verify the targeting of the 3'UTR of CD44 mRNA by miR-150. For that purpose, C666-1 cells were transfected with a wild-type or mutant CD44 3'-UTR reporter together with a pre-miR-150 (miR-150 mimic) or an miRNA mimic control. The results in Fig. 5C revealed that miR-150 could significantly reduce the wild-type 3'-UTR reporter activity, whereas the effect of miR-150 on the mutant 3'-UTR was not significant. These observations indicate that CD44 is a novel target of miR-150 in NPC cells. In a functional study, transfection of C666-1 cells with pre-miR-150 resulted in a significant reduction in the migration of tumor cells ( Fig. 5D ).
Furthermore, this inhibitory effect could be attenuated when the cells were transfected
with both pre-miR-150 and pCMV-CD44. miR-150 overexpression inhibits tumor cell migration but not spheroid growth. As mentioned above, siRNA knockdown of CD44 only inhibited the migration but not the growth of NPC tumor spheres. Two biological assays, namely spheroid formation assay and tumor cell migration assay, were then used to further evaluate the functional implication of the miR-150/CD44 axis in NPC cells. NPC cells were transfected with the precursor of miR-150 (pre-miR-150). The results in Fig. 5D revealed that the migratory activity of pre-miR-150-transfected NPC cells was significantly lower than that of control-transfected cells. However, exogenous miR-150 had no significant effect on the formation of tumor spheres (Fig. 5E ). Taken together, these data suggest that the miR-150/CD44 axis is involved in the regulation of NPC cell migration.
Discussion
CD44 is a cell surface membrane molecule involved in the regulation of diverse functions in tumor cells in a context-dependent manner (4) . It has previously been shown that CD44 may interact with hyaluronic acid and stimulate the proliferation of endothelial cells (27) . In colon cancer, CD44 has been shown to regulate both the in vitro and in vivo growth of xenografts in animals (28) . CD44 has also been implicated in self-renewal and maintenance of pluripotency (4) . Another well-known function of CD44 is the regulation of tumor cell migration via interaction with ezrin (29) . In NPC, an association between the expression of CD44 and the characteristics of the epithelial-mesenchymal transition (EMT) has previously been reported (30) . However, the biological function of CD44 in NPC cells has not been fully examined to date. In view of the importance of CD44 in the regulation of tumor cell activities, the present study sought to further examine the underlying mechanisms of ICG-001-induced downregulation of CD44 expression in NPC cells.
A clear association between ICG-001-mediated inhibition of in vitro migration of NPC cells and downregulated expression of CD44 at the mRNA and protein level was observed. ICG-001 is a CBP antagonist that has previously been demonstrated to block the interaction between β-catenin and CBP, and to inhibit the downstream transcription of a subset of Wnt target genes (31) . The reduced expression of CD44 mRNA observed in the present study could be explained by the fact that CD44 is a well-known Wnt downstream target gene (32) . Notably, a significant increase in the expression of miR-150 was also observed in ICG-001-treated NPC cells. Previous studies demonstrated that miR-150 is one of the miRNAs downregulated in NPC (25, 33) . Further bioinformatics analysis using TargetScan indicated that CD44 is a P r o o f predicted target of miR-150. Using the CD44 3'-UTR luciferase reporter assay, the present study confirmed that CD44 is a novel target of miR-150. This observation suggested that the restored expression of miR-150 may be an additional mechanism contributing to the reduced protein expression of CD44 in ICG-001-treated NPC cells. (DKC1) and RAC-beta serine/threonine-protein kinase (AKT2) (41) . In esophageal squamous cell carcinoma, the tumor-suppressive activity of miR-150 was attributed to its capacity to target the EMT inducer Zinc finger E-box-binding homeobox 1 (ZEB1) (40) . These observations suggest that miR-150 acts as a tumor suppressor in several types of tumor, and its effect is cellular context-dependent.
In the present study, a novel function of miR-150 was identified, namely its capacity for targeting CD44 and inhibiting the migration of NPC cells. This 
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